Thrivent Financial For Lutherans Vaxart, Inc. Transaction History

Thrivent Financial For Lutherans

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 19, 2021	SELL	$5.06 - $10.78 $2.84 Million - $6.04 Million	-560,322 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.64 - $23.33 $3.05 Million - $12.6 Million	540,476 Added 2723.35%	560,322 $3.39 Million
Q4 2020 Feb 16, 2021	BUY	$3.5 - $7.98 $69,461 - $158,371	19,846 New	19,846 $113,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.